Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


suck pdf from google scholar
unlimited free pdf from europmc35085325    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

Nephropedia Template TP Text

Twit Text FOAVip

Twit Text #

English Wikipedia

  • Identification of potentially anti-COVID-19 active drugs using the connectivity MAP #MMPMID35085325
  • Bonnet R; Mariault L; Peyron JF
  • PLoS One 2022[]; 17 (1): e0262751 PMID35085325show ga
  • Drug repurposing can be an interesting strategy for an emergency response to the severe acute respiratory syndrome-coronavirus-2, (SARS-COV-2), the causing agent of the coronavirus disease-19 (COVID-19) pandemic. For this, we applied the Connectivity Map (CMap) bioinformatic resource to identify drugs that generate, in the CMap database, gene expression profiles (GEP) that negatively correlate with a SARS-COV-2 GEP, anticipating that these drugs could antagonize the deleterious effects of the virus at cell, tissue or organism levels. We identified several anti-cancer compounds that target MDM2 in the p53 pathway or signaling proteins: Ras, PKBbeta, Nitric Oxide synthase, Rho kinase, all involved in the transmission of proliferative and growth signals. We hypothesized that these drugs could interfere with the high rate of biomass synthesis in infected cells, a feature shared with cancer cells. Other compounds including etomoxir, triacsin-c, PTB1-IN-3, are known to modulate lipid metabolism or to favor catabolic reactions by activating AMPK. Four different anti-inflammatory molecules, including dexamethasone, fluorometholone and cytosporone-b, targeting the glucocorticoid receptor, cyclooxygenase, or NUR77 also came out of the analysis. These results represent a first step in the characterization of potential repositioning strategies to treat SARS-COV-2.
  • |*COVID-19 Drug Treatment[MESH]
  • |Anti-Inflammatory Agents/therapeutic use[MESH]
  • |Antineoplastic Agents/therapeutic use[MESH]
  • |Antiviral Agents/therapeutic use[MESH]
  • |Computational Biology/methods[MESH]
  • |Databases, Genetic[MESH]
  • |Drug Repositioning/*methods[MESH]
  • |Gene Expression/drug effects[MESH]
  • |Humans[MESH]
  • |Models, Theoretical[MESH]
  • |Pandemics[MESH]
  • |Pharmaceutical Preparations[MESH]
  • |SARS-CoV-2/*drug effects/pathogenicity[MESH]
  • |Transcriptome/drug effects[MESH]

  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    e0262751 1.17 2022